The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Specifically, when SC pembrolizumab was given to patients every 6 weeks with a median injection time of 2 minutes (4.8 mL) plus chemotherapy, noninferiority of area under the curve (AUC) exposure of ...

The subcutaneous (SC) administration of pembrolizumab (Keytruda) combined with berahyaluronidase alfa (MK-3475A; SC pembrolizumab) led to noninferior pharmacokinetics (PK) when given with chemotherapy ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, ... (8.4% vs 8.7%, respectively). Injection site reactions were infrequent (2.4%) and mild in severity.

The trial met its primary endpoints, with subcutaneous pembrolizumab plus chemotherapy demonstrating noninferior pharmacokinetics with a median injection time of two minutes versus IV Keytruda plus ...

In the 3475A-D77 trial, subcutaneous pembrolizumab, administered every six weeks with a median injection time of two minutes (4.8 mL) along with chemotherapy, demonstrated noninferiority of area under ...

The study met its primary endpoints, demonstrating non-inferior pharmacokinetics (PK) for subcutaneous pembrolizumab administered with chemotherapy with a median injection time of two minutes, versus ...

“The median injection time for pembrolizumab SC was 2 minutes for a volume of 4.8 mL,” said study presenter Enriqueta Felip, MD, PhD, of Vall d’Hebron Institute of Oncology in Barcelona.

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...

The incidence of local injection site reactions for subcutaneous pembrolizumab with chemotherapy was 2.4%, all of which were low grade. Treatment-related adverse events (TRAEs) led to discontinuation ...

Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis ...